ETHZilla

ETHZilla Buyback Yield

The Buyback Yield of ETHZilla (ETHZ) as of Nov 18, 2026 is 69,923.23 %.

Buyback Yield

69,923.23 %

Last updated:

Buyback Yield of ETHZilla is 2025 69,923.23 % . Buyback Yield of ETHZilla was 2024 0.00 . It decreases by % higher compared to the previous year.

The ETHZilla Buyback Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Buyback Yield
Date
Buyback Yield
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
13.61 USD
Jan 1, 2022
1.53 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
69,923.23 USD
The ETHZilla Buyback Yield history
YEARBuyback YieldYoY
69,923.23 %—
0.00—
0.00-100.00%
1.53 %-88.73%
13.61 %—
0.00—
0.00—
0.00—
0.00-100.00%
0.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ETHZilla Stock analysis

What does ETHZilla do? 180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases, focusing on three research programs: Fibrosis and Anti-TNF, SCAs, and a7nAChR. The Fibrosis and Anti-TNF program targets conditions such as Dupuytren’s contracture, frozen shoulder, polycystic ovarian disease (POCD), and nonalcoholic steatohepatitis (NASH). The SCAs program addresses chronic pain and early arthritis, while the a7nAChR program focuses on smoking cessation and ulcerative colitis. The company generates revenue through the development and potential future sale of these pharmaceutical products, targeting patients and healthcare providers in the treatment of inflammatory and chronic pain conditions. The company operates as a research and development firm with a pipeline of drugs in separate areas of inflammation. Its products are designed to treat specific diseases within inflammation, including Dupuytren’s contracture, frozen shoulder, POCD, NASH, chronic pain, early arthritis, and ulcerative colitis. Revenue is derived from the commercialization of these pharmaceuticals once they reach the market, with no mention of current sales or partnerships in the business description. 180 Life Sciences Corp. is structured around three distinct drug development programs, each targeting a specific disease area. The Fibrosis and Anti-TNF program covers multiple inflammatory conditions, while SCAs and a7nAChR address chronic pain and smoking-related health issues, respectively. The company’s revenue model relies on the successful development and market entry of these pharmaceuticals, with no indication of current revenue streams beyond its R&D phase. ETHZilla is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ETHZilla stock

Buyback Yield of ETHZilla is 69,923.23 % in 2025.

On Eulerpool you can find the complete historical development of Buyback Yield ETHZilla since 2006 – with annual values, charts, and detailed analysis.

Buyback yield measures the percentage of market cap returned to shareholders through share repurchases. It complements dividend yield in assessing total shareholder returns.

To evaluate Buyback Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Buyback Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Buyback Yield's ETHZilla with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ETHZilla

All Key Metrics — ETHZilla